Metsera initiated with an Overweight at Wells Fargo

Wells Fargo analyst Cerena Chen initiated coverage of Metsera (MTSR) with an Overweight rating and $65 price target The company “stands out” in a “crowded” obesity landscape with assets that promise monthly dosing and competitive efficacy without tolerability tradeoffs, the analyst tells investors in a research note. Wells sees a good risk/reward at current levels, saying data over the next year will strengthen Metsera’s “differentiated profile.” The firm points out the company’s platform so far has delivered assets with 18- and 19-day half-lives.